🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

BioInvent International clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our USA and UK registers with BioInvent International as lead sponsor. Synced 26 Sep 2026
4Current trials
3Recruiting now
6Drugs in these trials
2Trial registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

BioInvent International is the lead sponsor of 4 current clinical trials in our USA and UK registers. 3 are recruiting patients now. All registered phases are Phase 1/2. The drugs named most often in its trials are Acalabrutinib, Ipilimumab and Paclitaxel. The most-studied condition is Melanoma Metastatic.

ClinicalTrials.gov trials by status

  • Recruiting375%
  • Active, closed125%

Trials by phase

  • Phase 1/24100%
01

Clinical trials sponsored by BioInvent International

4 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
NCT04752826 · ClinicalTrials.gov ↗ · Advanced Malignancies, Ovarian Cancer, T-cell Lymphoma
Phase 1/2 Recruiting 2021-01 UK, USA
A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL
NCT03571568 · ClinicalTrials.gov ↗ · Indolent B-Cell Non-Hodgkin Lymphoma
Phase 1/2 Recruiting 2018-05 USA
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
NCT04219254 · ClinicalTrials.gov ↗ · Solid Tumor, Adult
Phase 1/2 Recruiting 2020-06 USA
Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma
NCT06784648 · Melanoma Metastatic, Melanoma of Skin, Melanoma BRAF V600E/K Mutated
Phase 1/2 Active, closed 2024-12 UK

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in BioInvent International trials

6 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in BioInvent International trials

10 conditions
Melanoma Metastatic1Melanoma of Skin1Melanoma BRAF V600E/K Mutated1Melanoma Recurrent1Advanced Malignancies1Ovarian Cancer1T-cell Lymphoma1Melanoma1Indolent B-Cell Non-Hodgkin Lymphoma1Solid Tumor, Adult1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in USA33
Clinical trials in UK21

A trial with sites in more than one country appears in each of those registers.

05

Questions about BioInvent International trials

How many clinical trials does BioInvent International sponsor?

BioInvent International is the lead sponsor of 4 current trials on ClinicalTrials.gov in our USA and UK registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are BioInvent International trials recruiting?

Yes. 3 of its 4 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is BioInvent International testing?

Its current trials name 6 drugs and biologicals as interventions. The most frequent are Acalabrutinib (1), Ipilimumab (1), Paclitaxel (1), Pembrolizumab (1) and Pembrolizumab KEYTRUDA (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.